Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the …
$7.70-2.90%
报价 2026-11-13
市值
$78.5M
EV
$92.1M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -57.4%
$4.18$18.09
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ATRAAtara Biotherapeutics, Inc. | $78.5M | -2.9% | -86.5% | 91.4% | – | – | – | |
| OVIDOvid Therapeutics Inc. | $479.4M | -0.4% | -87.9% | 100% | – | – | – | |
| STTKShattuck Labs, Inc. | $473.6M | -3.3% | -91.7% | -82% | – | – | – | |
| IFRXInflaRx N.V. | $172.4M | -5.6% | – | 48,201.6% | – | – | – | |
| STROSutro Biopharma, Inc. | $163M | +2.4% | -66.8% | 97.2% | – | – | – | |
| ORMPOramed Pharmaceuticals Inc. | $161.3M | -7.9% | -40.0% | 0% | 1.9x | 2.4x | – | |
| MGNXMacroGenics, Inc. | $140.6M | -3.9% | -21.0% | 50.4% | – | – | – | |
| COYACoya Therapeutics, Inc. | $73.4M | -4.3% | -61.0% | 99.9% | – | – | – | |
| CSBRChampions Oncology, Inc. | $65.5M | +1.2% | +11.6% | 43.4% | – | – | – | |
| 同行中位数 | – | – | -61.0% | 73.8% | 1.9x | 2.4x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。